Objective

2

To evaluate the clinical efficacy of

Xuefu Zhuyu Capsule

（血府逐瘀胶囊） in treating angina pectoris of coronary heart disease （CHD）.

Methods

2

In this multicenter prospective cohort study， a total of 543 CHD patients with angina pectoris were included， and they were divided into treatment group （262 cases） and control group （281 cases） according to whether or not

Xuefu Zhuyu Capsule

was used. Both groups were given western medicine routine treatment， while the treatment group additionally received oral

Xuefu Zhuyu Capsule

（0.4 g each capsule）， 6 capsules each time， twice a day. The treatment course of both groups was 8 weeks. Before and after treatment， the scores of Seattle Angina Questionnaire （SAQ） including physical limitation （PL）， angina stability （AS）， angina frequency （AF）， treatment satisfaction （TS）， and disease perception （DP） were compared between the two groups， and the SAQ scores were analyzed by multiple linear regression. According to different types （stable angina pectoris or unstable angina pectoris）， gender （male or female）， age （＜65 years old or ≥65 years old） and hypertension （yes or no）， the SAQ scores of the two groups after treatment were further compared.

Results

2

During the study， 41 cases fell off， and finally 253 cases in treatment group and 249 cases in the control group were included in the analysis. The scores of PL， AS， AF， TS and DP in SAQ of both groups significantly increased after treatment， and all SAQ scores in the treatment group were better than those in the control group （

P

＜0.05）. Compared to those in the control group， SAQ scores of patients with unstable angina pectoris in the treatment group were significantly increased after treatment （

P

＜0.05）； the scores of AS， TS and DP of male patients and PL and AF of female patients significantly increased （

P

＜0.05）； the PL， AS and DP of patients ≥65 years old increased after treatment， as well as the scores of AS， AF， TS and DP of patients ＜65 years old （

P

＜0.05）. After treatment， all SAQ scores of patients concomitant with hypertension were significantly higher in the treatment group than in the control group （

P

＜0.05）. After adjusting for potential confounding factors such as age， gender， comorbidities， and treatment medications by multiple linear regression analysis，

Xuefu Zhuyu Capsules

combined with western medicine routine treatment could significantly improve the SAQ score （

P

＜0.05）.

Conclusion

2

Xuefu Zhuyu Capsule

in addition to western medicine routine treatment can significantly improve body movement and angina pectoris， thereby improving the quality of life of CHD patients with angina pectoris. The effect may be more obvious in patients with unstable angina or concomitant with hypertension.